Long-term treatment with rosiglitazone and metformin reduces the extent of, but does not prevent, islet amyloid deposition in mice expressing the gene for human islet amyloid polypeptide.

@article{Hull2005LongtermTW,
  title={Long-term treatment with rosiglitazone and metformin reduces the extent of, but does not prevent, islet amyloid deposition in mice expressing the gene for human islet amyloid polypeptide.},
  author={Rebecca L Hull and Zhen-ping Shen and Melissah R Watts and Kazuhiro Kodama and Darcy B. Carr and Kristina M Utzschneider and Sakeneh Zraika and Feng Wang and Steven E Kahn},
  journal={Diabetes},
  year={2005},
  volume={54 7},
  pages={
          2235-44
        }
}
Islet amyloid deposition in type 2 diabetes is associated with reduced beta-cell mass. Therefore, interventions aimed at reducing islet amyloid formation may help preserve beta-cell mass in type 2 diabetes. Rosiglitazone and metformin act by different mechanisms to improve insulin sensitivity and thereby reduce beta-cell secretory demand, resulting in decreased release of insulin and islet amyloid polypeptide (IAPP), the unique constituent of islet amyloid deposits. We hypothesized that this… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 32 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 51 REFERENCES

Validation of whole-body R.L

  • P Mystkowski, E Shankland, +5 authors MW Schwartz
  • HULL AND ASSOCIATES DIABETES,
  • 2005

Similar Papers

Loading similar papers…